Gilead Sciences rectal gel can prevent HIV infection: New study
Study findings demonstrated that the gel, when applied to the vagina in previous trials, reduced HIV infection by 34% compared with placebo, which urged researchers to find out
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.